Pay vs Performance Disclosure, Table


			Average Summary Compensation Table Total for non-PEO NEOs ($)		Value of Initial Fixed $100 Investment Based on:
Year	Summary Compensation Table Total for PEO ($)	Compensation Actually Paid to PEO ($)		Average Compensation Actually Paid to non-PEO NEOs ($)	Total Shareholder Return ($)	Peer Group Total Shareholder Return ($)	Net Income (in $ millions)	Reported Net Sales Growth (%)
2025	21,401,495	24,776,477	4,638,269	5,450,024	151.03	148.36	3,246	11.2
2024	21,979,369	48,190,172	6,361,985	12,965,592	153.30	129.46	2,993	10.2
2023	20,767,847	42,471,951	6,072,179	11,389,954	126.33	126.21	3,165	11.1
2022	18,563,214	11,419,346	5,246,489	3,676,892	102.05	123.67	2,358	7.8
2021	16,359,898	27,844,502	5,769,074	8,859,654	110.22	126.13	1,994	19.2

Company Selected Measure Name

reported net sales growth

Named Executive Officers, Footnote

Average Summary Compensation Table Total for non-PEO NEOs: This column represents the average total compensation value as

reported in the Summary Compensation Table for Named Executive Officers other than the Principal Executive Officer. The following

table lists by year the non-PEO NEOs included in the calculation of the average values in the table:


2025	2024	2023	2022	2021
Preston W. Wells	Glenn S. Boehnlein	Glenn S. Boehnlein	Glenn S. Boehnlein	Glenn S. Boehnlein
Spencer S. Stiles	J. Andrew Pierce	J. Andrew Pierce	J. Andrew Pierce	J. Andrew Pierce
J. Andrew Pierce	Spencer S. Stiles	Spencer S. Stiles	Spencer S. Stiles	Spencer S. Stiles
Viju S. Menon	Viju S. Menon	Viju S. Menon	Viju S. Menon	Viju S. Menon
Glenn S. Boehnlein				Timothy J. Scannell

Peer Group Issuers, Footnote

Peer Group Total Shareholder Return: This column represents the total returns (including reinvestments of dividends) of the S&P 500

Health Care Index used for purposes of Item 201(e) of Regulation S-K. Refer to Item 5 in our 2025 Annual Report on Form 10-K for

further information on the peer group. Values in this column assume $100 was invested on December 31, 2020.

PEO Total Compensation Amount

$ 21,401,495

$ 21,979,369

$ 20,767,847

$ 18,563,214

$ 16,359,898

PEO Actually Paid Compensation Amount

$ 24,776,477

48,190,172

42,471,951

11,419,346

27,844,502

Adjustment To PEO Compensation, Footnote

Compensation Actually Paid to PEO: This column represents the compensation actually paid value for our PEO calculated according

to the methodology prescribed by the SEC. The following table summarizes the adjustments to the Summary Compensation Table value

which resulted in the compensation actually paid amount for our PEO in 2025:


Year	Summary Compensation Table Total ($)	Grant Date Fair Value of Equity Awards Granted During the Year ($)	Year-End Fair Value of Equity Awards Granted During the Year that Remain Unvested as of Year-End ($)(1)	Change in Fair Value as of Year- End of Equity Awards Granted in Any Prior Year that Remain Unvested as of Year-End ($)(1)	Fair Value of Awards Granted During the Year that Vested During the Year ($)(1)	Change in Fair Value as of the Vesting Date of Equity Awards Granted in Any Prior Year that Vested During the Year ($)(1)	Compensation Actually Paid ($)
2025	21,401,495	(16,684,917)	12,568,907	3,800,709	—	3,690,283	24,776,477

______________

(1)The fair value of equity awards (performance stock units, restricted stock units and stock option awards) is calculated in accordance with the

Compensation — Stock Compensation Topic of the FASB Codification. Stock option values are derived using the Black-Scholes option pricing

model. The assumptions (risk-free interest rate, expected dividend yield, expected stock price volatility and expected option life) used in the

calculation of the fair value of stock option awards at each measurement date for purposes of determining the compensation actually paid amounts

have been updated, as necessary, relative to the assumptions used in the grant date fair value calculations for the respective stock option awards.

Non-PEO NEO Average Total Compensation Amount

$ 4,638,269

6,361,985

6,072,179

5,246,489

5,769,074

Non-PEO NEO Average Compensation Actually Paid Amount

$ 5,450,024

12,965,592

11,389,954

3,676,892

8,859,654

Adjustment to Non-PEO NEO Compensation Footnote

Average Compensation Actually Paid to non-PEO NEOs: This column represents the average compensation actually paid value for

our non-PEO NEOs calculated according to the methodology prescribed by the SEC. The following table summarizes the average

adjustments to the average Summary Compensation Table value which resulted in the average compensation actually paid amount for

our non-PEO NEOs in 2025:


Year	Average Summary Compensation Table Total ($)	Average Grant Date Fair Value of Equity Awards Granted During the Year ($)	Average Year- End Fair Value of Equity Awards Granted During the Year that Remain Unvested as of Year-End ($)(1)	Average Change in Fair Value as of Year-End of Equity Awards Granted in Any Prior Year that Remain Unvested as of Year-End ($)(1)	Average Fair Value of Awards Granted During the Year that Vested During the Year ($)(1)	Average Change in Fair Value as of the Vesting Date of Equity Awards Granted in Any Prior Year that Vested During the Year ($)(1)	Average Compensation Actually Paid ($)
2025	4,638,269	(3,026,237)	2,278,059	805,683	2,070	752,180	5,450,024

______________

(1)The fair value of equity awards (performance stock units, restricted stock units, the stock award granted to Mr. Wells related to his leadership of an

employee resource group and stock option awards) is calculated in accordance with the Compensation — Stock Compensation Topic of the FASB

Codification. Stock option values are derived using the Black-Scholes option pricing model. The assumptions (risk-free interest rate, expected

dividend yield, expected stock price volatility and expected option life) used in the calculation of the fair value of stock option awards at each

measurement date for purposes of determining the compensation actually paid amounts have been updated, as necessary, relative to the

assumptions used in the grant date fair value calculations for the respective stock option awards.

Compensation Actually Paid vs. Total Shareholder Return

Relationship of Compensation Actually Paid and Our Total Shareholder Return

The compensation actually paid to our PEO and other NEOs was strongly aligned to our total shareholder return during the five-year

period of 2021 to 2025. This is largely a result of the significant weighting of equity-based compensation, which is directly linked to the

price of our Common Stock, in the pay program for the PEO and other NEOs.

Compensation Actually Paid vs. Net Income

Relationship of Compensation Actually Paid and Our Net Income

The compensation actually paid to our PEO and other NEOs had limited alignment to our reported net income during the five-year

period of 2021 to 2025. Reported net income is not used as a performance measure in the pay programs for our PEO and other NEOs,

nor is it used when determining any other component of pay for this group.

Compensation Actually Paid vs. Company Selected Measure

Relationship of Compensation Actually Paid and Our Reported Net Sales Growth

The compensation actually paid to our PEO and other NEOs was aligned to our reported net sales growth during the five-year period of

2021 to 2025. Our one-year reported net sales growth performance is used in the performance stock units program when calculating

our three-year average reported net sales growth performance relative to a comparison group of companies, which has represented

50% of the target award opportunity in each grant of performance stock units that is included in the calculation of compensation actually

paid during the five-year period of 2021 to 2025.

Total Shareholder Return Vs Peer Group

Relationship of Our Total Shareholder Return and the Peer Group Total Shareholder Return

Our cumulative total shareholder return during the five-year period of 2021 to 2025 was greater than that of the S&P 500 Health Care

Index.

Tabular List, Table

Reported net sales growth

Constant currency sales

Adjusted net earnings per diluted share growth

Adjusted operating income

Adjusted operating income margin

Total Shareholder Return Amount

$ 151.03

153.30

126.33

102.05

110.22

Peer Group Total Shareholder Return Amount

148.36

129.46

126.21

123.67

126.13

Net Income (Loss)

$ 3,246,000,000

$ 2,993,000,000

$ 3,165,000,000

$ 2,358,000,000

$ 1,994,000,000

Company Selected Measure Amount

0.112

0.102

0.111

0.078

0.192

PEO Name

Mr. Lobo

Additional 402(v) Disclosure

Summary Compensation Table Total for PEO: This column represents the total compensation value for our PEO as reported in the

Summary Compensation Table. Mr. Lobo was the PEO for each of the covered years in the table.

Total Shareholder Return: This column represents the total returns (including reinvestments of dividends) of our Common Stock

assuming $100 was invested on December 31, 2020.

Net Income: This column represents our net earnings (in $ millions) as reported in conformance with GAAP.

Measure:: 1

Non-GAAP Measure Description

Reported net sales growth

Reported Net Sales Growth: This column represents the annual percentage change in our reported net sales as reported in

conformance with GAAP. We believe this measure is the most important financial performance measure (that is otherwise not required

to be disclosed in the Pay versus Performance table) used in linking compensation actually paid to our PEO and other NEOs to our

performance for the most recently completed fiscal year. Sales metrics are prominently used in the NEOs' annual bonus plans and

performance stock unit awards. Our reported net sales growth in 2025 is a large factor in determining the fair value as of December 31,

2025 for three performance stock unit cycles (the grants of performance stock units made in 2023, 2024 and 2025) thereby significantly

influencing the 2025 total compensation actually paid amounts to our PEO and other NEOs.

Measure:: 2

Constant currency sales

Measure:: 3

Adjusted net earnings per diluted share growth

Measure:: 4

Adjusted operating income

Measure:: 5

PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table

Adjusted operating income margin

PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested

$ (16,684,917)

PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested

12,568,907

PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year

3,800,709

PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year

Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table

3,690,283

Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested

(3,026,237)

Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested

2,278,059

Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year

805,683

Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year

2,070

Award Timing Disclosures [Line Items]

$ 752,180

Award Timing Disclosure

12 Months Ended

Dec. 31, 2025

Feb. 05, 2025

USD ($)

$ / shares

Award Timing MNPI Disclosure

The Company provides the following discussion of the timing of option awards in relation to the disclosure of material nonpublic

information, as required by Item 402(x) of Regulation S-K. We have adopted a granting policy covering all stock awards (including stock

options), both off-cycle (including hire-on) and ongoing annual grants. Under the policy, stock awards are granted by the Compensation

and Human Capital Committee, subject to approval by the Board in the case of grants to non-employee directors, and approval by the

independent directors of the Board in the case of grants to the Chief Executive Officer. Generally, the granting of stock awards occurs

on a pre-determined schedule, as described below. The Compensation and Human Capital Committee has delegated to the Chief

Executive Officer the authority to make "off-cycle grants" to new employees as a result of the acquisition of another company, in

situations where we are seeking to attract a senior level hire or recognize an employee for significant achievements or in other special

circumstances. In 2025 we made off-cycle grants to new hires, including those who became employees as a result of an acquisition,

and to select employees to recognize significant achievements and create retention incentives. Annual limits for off-cycle grants are

defined both per individual employee (20,000 shares) and in the aggregate (300,000 shares), with shares issuable in connection with

awards other than stock options being counted against such limits as 2.86 shares under our 2011 Long-Term Incentive Plan, as

amended or restated from time to time (the "2011 Plan").

The fair market value of Stryker stock used to establish the exercise price of all options is the closing sales price per share as reported

for NYSE Composite Transactions for the last trading day prior to the grant date. No stock grant is backdated and the timing of the

public release of material information or the grant of any stock award is not established with the intent of unduly benefiting a grantee

under a stock award. The Compensation and Human Capital Committee and, with respect to the Chief Executive Officer’s stock

awards, the independent directors of the Board, do not take material nonpublic information into account when determining the timing

and terms of stock awards. Instead, the timing of grants is in accordance with the compensation cycle described below. Each annual

grant and off-cycle grant of equity-based compensation is awarded on a pre-determined date as follows:

•The annual grant of stock awards for employees is generally made on the date of the February meeting of the Board. The annual

grant of stock awards for non-employee directors is generally made on the date of the Board meeting that coincides with our

annual meeting of shareholders. Any change in the annual grant date for employees or non-employee directors must be made

with the prior approval of the Board.

•Off-cycle awards may be granted by the Chief Executive Officer, pursuant to delegated authority from the Compensation and

Human Capital Committee, on or around the first business day of May, August or November following the date of hire or the

determination that an award is warranted in other circumstances. Off-cycle awards are reported to the Compensation and

Human Capital Committee and the Board at their next regular meetings.

The stock awards to our NEOs have historically included performance stock units, stock options, and occasionally, restricted stock

units. Where permissible by law, we require U.S. employees who receive stock awards to sign a version of the Company's

confidentiality, non-competition and non-solicitation agreement. The terms and conditions of our stock awards include recoupment

provisions that are applicable in the event of a violation of the non-compete agreement to which each of our NEOs has agreed.

The Company has not timed the disclosure of material nonpublic information to affect the value of executive compensation. Any

coordination between a grant of stock awards and the release of information that could be expected to affect such grant’s value is

generally precluded by the granting policy and pre-determined schedule, using the methodology described above.

The information in the table below is provided in accordance with Item 402(x)(2) of Regulation S-K regarding the grant of stock options

in 2025 within four business days before, or within one business day after, the filing of a report on Forms 10-K, 10-Q, or 8-K disclosing

material nonpublic information. The stock options included in the table were granted on February 5, 2025 as part of the annual grant of

stock awards, which occurred within four business days of the Form 8-K that was filed on February 10, 2025 that disclosed the details

of a public debt offering.


Name	Grant Date	Number of Securities Underlying Award (#)	Exercise Price ($/sh)	Grant Date Fair Value ($)	Percentage Change in the Closing Market Price of the Securities Underlying the Award Between the Trading Day Ending Immediately Prior to the Disclosure of Material Nonpublic Information and the Trading Day Beginning Immediately Following the Disclosure of Material Nonpublic Information
Kevin A. Lobo	2/5/2025	48,936	392.39	6,920,781	(0.2)%
Preston W. Wells	2/5/2025	9,176	392.39	1,297,717	(0.2)%
Spencer S. Stiles	2/5/2025	13,458	392.39	1,903,300	(0.2)%
J. Andrew Pierce	2/5/2025	13,458	392.39	1,903,300	(0.2)%
Viju S. Menon	2/5/2025	8,258	392.39	1,167,889	(0.2)%

Award Timing Method

The Company has not timed the disclosure of material nonpublic information to affect the value of executive compensation. Any

coordination between a grant of stock awards and the release of information that could be expected to affect such grant’s value is

generally precluded by the granting policy and pre-determined schedule, using the methodology described above.

Award Timing Predetermined

true

Award Timing MNPI Considered

true

Award Timing, How MNPI Considered

The Company has not timed the disclosure of material nonpublic information to affect the value of executive compensation. Any

coordination between a grant of stock awards and the release of information that could be expected to affect such grant’s value is

generally precluded by the granting policy and pre-determined schedule, using the methodology described above.

MNPI Disclosure Timed for Compensation Value

false

Awards Close in Time to MNPI Disclosures, Table

The information in the table below is provided in accordance with Item 402(x)(2) of Regulation S-K regarding the grant of stock options

in 2025 within four business days before, or within one business day after, the filing of a report on Forms 10-K, 10-Q, or 8-K disclosing

material nonpublic information. The stock options included in the table were granted on February 5, 2025 as part of the annual grant of

stock awards, which occurred within four business days of the Form 8-K that was filed on February 10, 2025 that disclosed the details

of a public debt offering.


Name	Grant Date	Number of Securities Underlying Award (#)	Exercise Price ($/sh)	Grant Date Fair Value ($)	Percentage Change in the Closing Market Price of the Securities Underlying the Award Between the Trading Day Ending Immediately Prior to the Disclosure of Material Nonpublic Information and the Trading Day Beginning Immediately Following the Disclosure of Material Nonpublic Information
Kevin A. Lobo	2/5/2025	48,936	392.39	6,920,781	(0.2)%
Preston W. Wells	2/5/2025	9,176	392.39	1,297,717	(0.2)%
Spencer S. Stiles	2/5/2025	13,458	392.39	1,903,300	(0.2)%
J. Andrew Pierce	2/5/2025	13,458	392.39	1,903,300	(0.2)%
Viju S. Menon	2/5/2025	8,258	392.39	1,167,889	(0.2)%

Lobo [Member]

Kevin A. Lobo

48,936

$ 392.39

$ 6,920,781

(0.002)

Wells [Member]

Preston W. Wells

9,176

$ 392.39

$ 1,297,717

(0.002)

Stiles [Member]

Spencer S. Stiles

13,458

$ 392.39

$ 1,903,300

(0.002)

Pierce [Member]

J. Andrew Pierce

13,458

$ 392.39

$ 1,903,300

(0.002)

Menon [Member]

Viju S. Menon

8,258

$ 392.39

$ 1,167,889